Blood disorders including leukemia and lymphoma can be cured with unrelated donor (URD) hematopoietic cell transplantation (HCT) and cord blood transplantation (CBT). Post-transplant complications and mortality may be lowered through comprehensive HLA matching of the stem cell source. KIR-HLA interactions further define transplant outcome. The clinical practice of URD HCT and CBT today has several unmet needs. HLA identity of the URD does not guarantee that the patient will not develop life-threatening post-transplant complications, indicating the presence of undetected MHC region variation. For patients who lack matched URDs, the rules that govern permissible HLA mismatches are needed so as to broaden the availability of HCT to all patients in need. In CBT, the relevance of undetected disparity at HLA-A, B, C, DR, and DQ is unknown. Natural killer (NK)-mediated effects may further modulate transplant risks. Overall, clinical outcome is inferior for patients of non-Caucasian ethnicity. This project has two major goals. First, we will define the clinical importance of MHC residue variation after URD HCT and CBT by measuring the impact of HLA mismatching in non-Caucasian populations, identifying non-permissible HLA mismatches, and novel MHC resident genes. Second, we will define the clinical impact of KIR-HLA interactions, determine the molecular mechanisms underlying donor NK alloreactivity through a systematic evaluation of activating KIRs and haplotypes, and define mechanisms involved for the development of NK alloreactivity. These research questions will address the current roadblocks in URD HCT and CBT and provide novel laboratory-based information that can be translated to clinical practice for all patients of diverse racial background.
Even though blood disorders such as leukemia and lymphoma can be cured through transplantation of stem cells from a healthy unrelated donor or cord blood stem cells, patients suffer from life-threatening complications. The risks of complications after transplantation are caused by variation in the genetic code between the patient and the stem cells. This project will find the genes that are causing the complications so that the information may be used to select unrelated donors and cord blood stem cells that lower risks. In this way, patients can be cured of their cancer and live longer healthier lives.
|Tarek, N; Gallagher, M M; Chou, J F et al. (2015) KIR and HLA genotypes have no identifiable role in single-unit dominance following double-unit umbilical cord blood transplantation. Bone Marrow Transplant 50:150-2|
|Fernandez-Viña, Marcelo A; Wang, Tao; Lee, Stephanie J et al. (2014) Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation. Blood 123:1270-8|
|Boudreau, Jeanette E; Le Luduec, Jean-Benoît; Hsu, Katharine C (2014) Development of a novel multiplex PCR assay to detect functional subtypes of KIR3DL1 alleles. PLoS One 9:e99543|
|Petersdorf, E W; Malkki, M; Hsu, K et al. (2013) 16th IHIW: international histocompatibility working group in hematopoietic cell transplantation. Int J Immunogenet 40:2-10|
|Petersdorf, Effie W; Malkki, Mari; Horowitz, Mary M et al. (2013) Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. Blood 121:1896-905|
|Petersdorf, Effie W (2013) Genetics of graft-versus-host disease: the major histocompatibility complex. Blood Rev 27:1-12|
|Pittari, Gianfranco; Liu, Xiao-Rong; Selvakumar, Annamalai et al. (2013) NK cell tolerance of self-specific activating receptor KIR2DS1 in individuals with cognate HLA-C2 ligand. J Immunol 190:4650-60|
|Morishima, Yasuo; Kawase, Takakazu; Malkki, Mari et al. (2013) Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:1197-203|
|Mendolia, Franco; Klein, John P; Petersdorf, Effie W et al. (2013) Comparison of statistics in association tests of genetic markers for survival outcomes. Stat Med :|
|Petersdorf, Effie W (2013) The major histocompatibility complex: a model for understanding graft-versus-host disease. Blood 122:1863-72|
Showing the most recent 10 out of 21 publications